Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

被引：97
|
作者：
Aalders, Kim C. [1 ]
Tryfonidis, Konstantinos [1 ]
Senkus, Elbieta [2 ]
Cardoso, Fatima [3 ]
机构：
[1] European Org Res Treatment Canc, Dept Med, Brussels, Belgium
[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[3] Champalimaud Canc Ctr, Breast Unit, Lisbon, Portugal
来源：
CANCER TREATMENT REVIEWS | 2017年 / 53卷
关键词：
Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS PACLITAXEL; OPEN-LABEL; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; TUMOR-CELLS; FACTOR VEGF;
D O I：
10.1016/j.ctrv.2016.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：98 / 110
页数：13
相关论文
共 50 条
  • [1] Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
    Ayoub, Nehad M.
    Jaradat, Sara K.
    Al-Shami, Kamal M.
    Alkhalifa, Amer E.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
    Frandsen, Sofie
    Kopp, Sascha
    Wehland, Markus
    Pietsch, Jessica
    Infanger, Manfred
    Grimm, Daniela
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (39) : 5927 - 5942
  • [3] Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
    De Paepe, Boel
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 180 - 185
  • [4] Current status and future prospects for anti-angiogenic therapies in cancer
    Staton, Carolyn A.
    Brown, Nicola J.
    Reed, Malcolm W. R.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (09) : 961 - 979
  • [5] Target-based Anti-angiogenic Therapy in Breast Cancer
    Wehland, Markus
    Bauer, Johann
    Infanger, Manfred
    Grimm, Daniela
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (27) : 4244 - 4257
  • [6] Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
    Giulia, Martini
    Teresa, Troiani
    Claudia, Cardone
    Paolo, Vitiello Pietro
    Davide, Ciardiello
    Floriana, Morgillo
    Fortunato, Ciardiello
    Erika, Martinelli
    CURRENT CANCER THERAPY REVIEWS, 2019, 15 (03) : 184 - 191
  • [7] Anti-angiogenic therapy in the treatment of advanced renal cell cancer
    Board, Ruth E.
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    CANCER TREATMENT REVIEWS, 2007, 33 (01) : 1 - 8
  • [8] Anti-angiogenic factors in thoracic oncology: Successes, failures and prospects
    Marco, S.
    Tomasini, P.
    Greillier, L.
    Barlesi, F.
    REVUE DES MALADIES RESPIRATOIRES, 2011, 28 (10) : 1216 - 1229
  • [9] In pursuit of new anti-angiogenic therapies for cancer treatment
    Cai, Jun
    Han, Song
    Qing, Ruan
    Liao, Daiqing
    Law, Brian
    Boulton, Michael E.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 803 - 814
  • [10] Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
    Marques, Ines
    Araujo, Antonio
    de Mello, Ramon Andrade
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (44) : 7955 - 7971
12345